Insulet PODD Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| Drug Delivery | $3.3M-77.9% | $1.9M-83.9% | $7.1M-31.1% | $10.2M+25.9% | $14.9M+71.3% | |
| International | $242.9M+59.5% | $214.1M+50.8% | $202.1M+46.6% | $185.8M+44.9% | $152.3M+32.1% | |
| Total Omnipod products | $758.4M+36.9% | $781.8M+33.5% | $699.2M+31.1% | $639M+33.0% | $554M+27.9% | |
| U.S.Omnipod | $515.6M+28.4% | $567.8M+28.0% | $497.1M+25.7% | $453.2M+28.6% | $401.7M+26.4% | |
| Property, plant and equipment, net by Geography | ||||||
| Malaysia | $224.7M+42.4% | $220M+38.3% | $164.2M— | $160.9M— | $157.8M— | |
| Other | $136.4M+910% | $126.9M+1,208% | $23.2M— | $18.4M— | $13.5M— | |
| U.S. | $469.3M-0.4% | $472.5M-0.7% | $461.9M— | $465.9M— | $471.4M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insulet break its business down?
- Insulet (PODD) reports total revenue by product across 4 parts — Drug Delivery, International, Total Omnipod products and U.S.Omnipod. Each is extracted from the segment footnotes and tracked over time.
- Where does Insulet's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insulet's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
